US 11,998,616 B2
Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
Mark E. Davis, Pasadena, CA (US); and Emily A. Wyent, Sherman Oaks, CA (US)
Assigned to California Institute of Technology, Pasadena, CA (US)
Filed by California Institute of Technology, Pasadena, CA (US)
Filed on Mar. 29, 2021, as Appl. No. 17/215,443.
Application 17/215,443 is a continuation of application No. 16/438,762, filed on Jun. 12, 2019, abandoned.
Claims priority of provisional application 62/684,593, filed on Jun. 13, 2018.
Prior Publication US 2021/0220483 A1, Jul. 22, 2021
Int. Cl. A61K 47/69 (2017.01); A61K 9/16 (2006.01); A61K 31/137 (2006.01); A61K 31/4045 (2006.01); A61K 31/4745 (2006.01); B82Y 5/00 (2011.01); C07K 16/32 (2006.01)
CPC A61K 47/6935 (2017.08) [A61K 9/1641 (2013.01); A61K 31/137 (2013.01); A61K 31/4045 (2013.01); A61K 31/4745 (2013.01); C07K 16/32 (2013.01); B82Y 5/00 (2013.01); Y10S 977/773 (2013.01); Y10S 977/906 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A method for slowing growth of a brain tumor by 82%-94%, the method comprising systemically administering, to a subject having the brain tumor, a nanoparticle comprising:
(a) a nanoparticle core comprising a mucic acid-containing polymer;
(b) transferrin joined to the nanoparticle core by a nitrophenyl boronic ester linkage to vicinal diols of the mucic acid-containing polymer;
(c) trastuzumab; and
(d) camptothecin.